AUTHORS
Zhao Peiqi, MD, Keshu Zhou, PhD2, Kaiyang Ding, MD3, Liqun Zou, MD4, Hui Zhou5, Li Zheng6, Yunyi Liu7, Huilai Zhang, PhD8
AFFILIATIONS
1 Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
2 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
3 Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China
4 West China Hospital of Sichuan University, Chengdu, China
5 Hunan Cancer Hospital, The affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
6 West China Hospital of Sichuan University, Chengdu, China
7 Gewu Biotechnology (Jiangsu) Co., Ltd, Wuxi, China
8 Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
ABSTRACT
Background:
EZH2 is a histone methyltransferase that functions as an oncogenic driver in certain non-Hodgkin lymphomas (NHLs) through gain-of-function mutations or overexpression. It has been reported that EZH1, a close homolog, may compensate EZH2 inhibition, suggesting that concurrent inhibition of both EZH2 and EZH1 may be needed to obtain more complete and durable antitumor responses. GW5282 is a potent and highly selective EZH1/2 dual inhibitor. In preclinical B-cell and T-cell lymphoma models, GW5282 exhibited significant antitumor activity as a single agent and profound synergistic antitumor effect when combined with other antitumor drugs. Ongoing phase 1/2 studies showed that GW5282 has potent antitumor activities in both B-cell and T-cell lymphomas with excellent clinical safety profile.
Aims
To evaluate efficacy and safety of GW5282 monotherapy in patients with relapsed/refractory (r/r) NHLs.
Methods:
This first-in-human study of GW5282 employs a dose-escalation phase primarily guided by the Bayesian Optimal Interval (BOIN) Design. Eligible participants are patients with r/r NHLs who have exhausted prior standard anti-lymphoma therapies. The primary endpoint is to assess the safety and tolerability of GW5282.
Results:
As of the data cut-off date on July 15, 2026, a total of 31 patients had been enrolled in the dose-escalation phase and received GW5282 as monotherapy at doses ranging from 40 mg to 180 mg twice daily (BID). The median age was 59.0 years (range: 36–74), and patients had received a median of two prior lines of systemic therapy (range: 1–7). One patient had undergone prior hematopoietic stem cell transplantation, and 48.4% of patients presented with elevated lactate dehydrogenase at baseline. Histological subtypes included follicular lymphoma (FL, 58.1%), large B-cell lymphoma (LBCL, 12.9%), and mature T-cell lymphoma (29.0%).
GW5282 was well tolerated up to 180 mg BID dose level. The most frequently reported adverse events were cytopenias, which were clinically manageable. No dose-limiting toxicities were observed, and no patient discontinued treatment or required dose reduction due to drug-related adverse events. Grade 3 or higher adverse events were observed in 35.5% of patients across all dose levels, and serious adverse events were experienced by 12.9%. As the maximum tolerated dose had not been reached, dose escalation remained ongoing.
Preliminary pharmacokinetic data were available for 22 patients across the dose-escalation cohorts. Systemic exposure increased in an approximately dose-proportional manner across the evaluated dose range from 40 mg to 180 mg. GW5282 was rapidly absorbed, with terminal t1/2 of approximately 12 hours following a single dose. Approximately 90% reduction in H3K27me3 was achieved at the dose levels of 40 mg and above.
Tumor responses were assessed by investigators per the Lugano 2014 criteria. Among patients with at least one post-baseline tumor evaluation, irrespective of dose level, the objective response rates (ORR) were 50.0% (7/14) in FL and 66.7% (4/6) in T-cell lymphoma. The median time to response was 8 weeks (range: 7-15). At the data cut-off date, no patient who achieved remission experienced disease progression, and the earliest response had lasted >9.5 months and continued to be maintained.
Dose escalation and enrolment at higher dose levels were ongoing at the time of analysis. EZH2 mutation status will be determined retrospectively in future analyses.
Conclusion:
GW5282 showed encouraging safety and efficacy in multiple r/r NHLs. Objective responses were observed even at low dose levels in previously heavily treated patients. These observations provide a strong rationale for advancing GW5282 into later-stage development, both as monotherapy and in rationally designed combinations.
DISCLOSURES
Zhao Peiqi, MD: No relevant conflicts of interest to declare.